Advertisement
Research Article Free access | 10.1172/JCI106059
1Molecular Disease Branch, National Heart Institute, National Institutes of Health, Bethesda, Maryland 20014
Find articles by Mize, C. in: JCI | PubMed | Google Scholar
1Molecular Disease Branch, National Heart Institute, National Institutes of Health, Bethesda, Maryland 20014
Find articles by Herndon, J. in: JCI | PubMed | Google Scholar
1Molecular Disease Branch, National Heart Institute, National Institutes of Health, Bethesda, Maryland 20014
Find articles by Blass, J. in: JCI | PubMed | Google Scholar
1Molecular Disease Branch, National Heart Institute, National Institutes of Health, Bethesda, Maryland 20014
Find articles by Milne, G. in: JCI | PubMed | Google Scholar
1Molecular Disease Branch, National Heart Institute, National Institutes of Health, Bethesda, Maryland 20014
Find articles by Follansbee, C. in: JCI | PubMed | Google Scholar
1Molecular Disease Branch, National Heart Institute, National Institutes of Health, Bethesda, Maryland 20014
Find articles by Laudat, P. in: JCI | PubMed | Google Scholar
1Molecular Disease Branch, National Heart Institute, National Institutes of Health, Bethesda, Maryland 20014
Find articles by Steinberg, D. in: JCI | PubMed | Google Scholar
Published June 1, 1969 - More info
The rate of oxidation of phytanic acid-U-14C to 14CO2 in three patients with Refsum's disease was less than 5% of that found in normal volunteers. In contrast, the rate of oxidation of α-hydroxyphytanic acid-U-14C and of pristanic acid-U-14C to 14CO2, studied in two patients, while somewhat less than that in normal controls, was not grossly impaired. These studies support the conclusion that the defect in phytanic acid oxidation in Refsum's disease is located in the first step of phytanic acid degradation, that is, in the alpha oxidation step leading to formation of α-hydroxyphytanic acid.
The initial rate of disappearance of plasma free fatty acid radioactivity after intravenous injection of phytanic acid-U-14C (t½ = 5.9 min) was slower than that seen with pristanic acid-U-14C (t½ = 2.7 min) or palmitic acid-1-14C (t½ = 2.5 min). There were no differences between patients and normal controls in these initial rates of free fatty acid disappearance for any of the three substrates tested.
There was no detectable lipid radioactivity found in the plasma 7 days after the injection of palmitic acid-1-14C or pristanic acid-U-14C in either patients or controls. After injection of phytanic acid-U-14C, however, the two patients showed only a very slow decline in plasma lipid radioactivity (estimated t½ = 35 days), in contrast to the normals who had no detectable radioactivity after 2 days. Incorporation of radioactivity from phytanic acid-U-14C into the major lipid ester classes of plasma was studied in one of the patients; triglycerides accounted for by far the largest fraction of the total present between 1 and 4 hr.